Illumina, Inc.
ILMNHealthcareNASDAQDiagnostics & Research · Last scanned Jun 1, 2026
Scan Results
Daily timeframeIllumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. With a market capitalization of $24.66B, it sits in large-cap territory. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Market Cap
$24.66B
Beta
1.42
P/E (TTM)
29.58
P/E (Fwd)
27.48
EPS (TTM)
$5.51
EPS (Fwd)
$5.93
ROE
33.8%
ROA
8.7%
Cash
$1.16B
Total Debt
$2.54B
Free CF
$845.6M
52W Change
101.0%
Annual Financials
Cash vs Debt
On the balance sheet, ILMN has $1.16B in cash with $2.54B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $845.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 33.8%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $4.58B (2022) to $4.34B (2025).
Investors considering Illumina, Inc. should weigh the typical risks associated with ILMN's sector, size, and financial profile against their own risk tolerance and investment objectives. No single metric tells the full story. Reviewing ILMN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.